Effect of polymorphism in Rhinolophus affinis ACE2 on entry of SARS-CoV-2 related bat coronaviruses

被引:7
|
作者
Li, Pei [1 ]
Hu, Jiaxin [1 ]
Liu, Yan [1 ]
Ou, Xiuyuan [1 ]
Mu, Zhixia [1 ]
Lu, Xing [1 ]
Zan, Fuwen [1 ]
Cao, Mengmeng [1 ]
Tan, Lin [1 ]
Dong, Siwen [1 ]
Zhou, Yao [1 ]
Lu, Jian [2 ]
Jin, Qi [1 ]
Wang, Jianwei [1 ]
Wu, Zhiqiang [1 ]
Zhang, Yingtao [3 ]
Qian, Zhaohui [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing, Peoples R China
[2] Peking Univ, Coll Life Sci, Beijing, Peoples R China
[3] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金; 北京市自然科学基金;
关键词
GENE;
D O I
10.1371/journal.ppat.1011116
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Author summaryBat CoV RaTG13 has zoonotic transmission potential, and interactions between S protein and ACE2 play essential roles. RaTG13 uses RaACE2 as an entry receptor, and there are at least seven polymorphic RaACE2 variants. The effect of RaACE2 polymorphism on entry of RaTG13 and other SARS-CoV-2 related bat CoV (SC2r-CoV) has not been determined. In this study, we find that RaTG13 S pseudovirions only highly efficiently transduce cells expressing RaACE2 among available 18 bat species commonly habituating in Southwestern China and Southeastern Asia, suggesting that there might be limited bat species including R. affinis susceptible to infection of RaTG13 virus. The RaACE2 polymorphism has a marked effect on the entry of RaTG13, whereas it shows a minimal effect on the entry of SARS-CoV-2 and SC2r-CoVs like BANAL-20-52, BANAL-20-236, and pangolin-CoV GD. Further sequence and mutagenesis analyses identify residues 34, 38, and 83 in RaACE2 and residues 501 and 505 in the S proteins critical for S protein and receptor interactions, indicating that RaTG13 might have not been well adapted to R. affinis bats. We also find that T372A substitution in RaTG13 S significantly enhances entry on all RaACE2 variants and several bat ACE2s, and immune evasion might contribute to the natural selection of T372 over A372 in bat S proteins. Altogether, our work provides detailed analyses of the effect of RaACE2 polymorphism on the entry of RaTG13 and other SC2r-CoVs and a better understanding of the entry and evolution of CoVs. Bat coronavirus RaTG13 shares about 96.2% nucleotide sequence identity with that of SARS-CoV-2 and uses human and Rhinolophus affinis (Ra) angiotensin-converting enzyme 2 (ACE2) as entry receptors. Whether there are bat species other than R. affinis susceptible to RaTG13 infection remains elusive. Here, we show that, among 18 different bat ACE2s tested, only RaACE2 is highly susceptible to transduction by RaTG13 S pseudovirions, indicating that the bat species harboring RaTG13 might be very limited. RaACE2 has seven polymorphic variants, RA-01 to RA-07, and they show different susceptibilities to RaTG13 S transduction. Sequence and mutagenesis analyses reveal that residues 34, 38, and 83 in RaACE2 might play critical roles in interaction with the RaTG13 S protein. Of note, RaACE2 polymorphisms have minimal effect on S proteins of SARS-CoV-2 and several SARS-CoV-2 related CoVs (SC2r-CoV) including BANAL-20-52 and BANAL-20-236 in terms of binding, membrane fusion, and pseudovirus entry. Further mutagenesis analyses identify residues 501 and 505 in S proteins critical for the recognition of different RaACE2 variants and pangolin ACE2 (pACE2), indicating that RaTG13 might have not been well adapted to R. affinis bats. While single D501N and H505Y changes in RaTG13 S protein significantly enhance the infectivity and minimize the difference in susceptibility among different RaACE2 variants, an N501D substitution in SARS-CoV-2 S protein displays marked disparity in transduction efficiencies among RaACE2 variants with a significant reduction in infectivity on several RaACE2 variants. Finally, a T372A substitution in RaTG13 S protein not only significantly increases infectivity on all RaACE2 variants, but it also markedly enhances entry on several bat ACE2s including R. sinicus YN, R. pearsonii, and R. ferrumeiqunum. However, the T372A mutant is about 4-fold more sensitive to neutralizing sera from mice immunized with BANAL-20-52 S, suggesting that the better immune evasion ability of T372 over A372 might contribute to the natural selective advantage of T372 over A372 among bat CoVs. Together, our study aids a better understanding of coronavirus entry, vaccine design, and evolution.
引用
收藏
页数:24
相关论文
共 50 条
  • [41] ACE2 Expression on the Keratinocytes and SARS-CoV-2 Percutaneous Transmission: Are they Related?
    Zhu, Ruixuan
    Shi, Yaqian
    Tan, Yixin
    Xiao, Rong
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (01) : 197 - 198
  • [42] Effect of ACE1 polymorphism rs1799752 on protein levels of ACE2, the SARS-CoV-2 entry receptor, in alveolar lung epithelium
    Jacobs, Merel
    Lahousse, Lies
    Van Eeckhoutte, Hannelore P.
    Wijnant, Sara R. A.
    Delanghe, Joris R.
    Brusselle, Guy G.
    Bracke, Ken R.
    ERJ OPEN RESEARCH, 2021, 7 (02)
  • [43] Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte
    Nunzia D’Onofrio
    Lucia Scisciola
    Celestino Sardu
    Maria Consiglia Trotta
    Marisa De Feo
    Ciro Maiello
    Pasquale Mascolo
    Francesco De Micco
    Fabrizio Turriziani
    Emilia Municinò
    Pasquale Monetti
    Antonio Lombardi
    Maria Gaetana Napolitano
    Federica Zito Marino
    Andrea Ronchi
    Vincenzo Grimaldi
    Anca Hermenean
    Maria Rosaria Rizzo
    Michelangela Barbieri
    Renato Franco
    Carlo Pietro Campobasso
    Claudio Napoli
    Maurizio Municinò
    Giuseppe Paolisso
    Maria Luisa Balestrieri
    Raffaele Marfella
    Cardiovascular Diabetology, 20
  • [44] The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
    Ahmad, Iqrar
    Pawara, Rahul
    Surana, Sanjay
    Patel, Harun
    TOPICS IN CURRENT CHEMISTRY, 2021, 379 (06)
  • [45] The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
    Iqrar Ahmad
    Rahul Pawara
    Sanjay Surana
    Harun Patel
    Topics in Current Chemistry, 2021, 379
  • [46] Cloaking the ACE2 receptor with salivary cationic proteins inhibits SARS-CoV-2 entry
    Yoshizato, Katsutoshi
    Taira, Toshio
    Sato-Matsubara, Misako
    Sekiguchi, Shizuko
    Yabunaka, Yoriko
    Kira, Yukimi
    Ohashi, Tetsu
    Daikoku, Atsuko
    Ofusa, Ken
    Kadono, Chiho
    Oikawa, Daisuke
    Matsubara, Tsutomu
    Nakagama, Yu
    Kido, Yasutoshi
    Tokunaga, Fuminori
    Ikeda, Kazuo
    Kaneko, Akira
    Kawada, Norifumi
    JOURNAL OF BIOCHEMISTRY, 2022, 172 (04): : 205 - 216
  • [47] Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte
    D'Onofrio, Nunzia
    Scisciola, Lucia
    Sardu, Celestino
    Trotta, Maria Consiglia
    De Feo, Marisa
    Maiello, Ciro
    Mascolo, Pasquale
    De Micco, Francesco
    Turriziani, Fabrizio
    Municino, Emilia
    Monetti, Pasquale
    Lombardi, Antonio
    Napolitano, Maria Gaetana
    Marino, Federica Zito
    Ronchi, Andrea
    Grimaldi, Vincenzo
    Hermenean, Anca
    Rizzo, Maria Rosaria
    Barbieri, Michelangela
    Franco, Renato
    Campobasso, Carlo Pietro
    Napoli, Claudio
    Municino, Maurizio
    Paolisso, Giuseppe
    Balestrieri, Maria Luisa
    Marfella, Raffaele
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [48] "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry
    Shukla, Satya Prakash
    Cho, Kwang Bog
    Rustagi, Vineeta
    Gao, Xiang
    Fu, Xinping
    Zhang, Shaun Xiaoliu
    Guo, Bin
    Udugamasooriya, D. Gomika
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [49] TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2
    Wang, Yinfang
    Fan, Yingzhe
    Huang, Yitong
    Du, Tao
    Liu, Zongjun
    Huang, Dekui
    Wang, Ying
    Wang, Nanping
    Zhang, Peng
    CELLULAR SIGNALLING, 2021, 85
  • [50] Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels
    Zeng, Qiru
    Antia, Avan
    Casorla-Perez, Luis Alberto
    Puray-Chavez, Maritza
    Kutluay, Sebla B.
    Ciorba, Matthew A.
    Ding, Siyuan
    MBIO, 2024, 15 (03):